Department of Surgery, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Am Surg. 2023 Aug;89(8):3516-3518. doi: 10.1177/00031348231161699. Epub 2023 Mar 8.
While reperfusion of autologous blood using the Cellsaver (CS) device is routine in cardiothoracic surgery, there is a paucity of evidence-based literature regarding its use in trauma. Utility of CS was compared in these two distinct populations at a Level 1 trauma center from 2017 to 2022. CS was successfully used in 97% and 74% of cardiac and trauma cases, respectively. The proportion of blood requirements provided by CS, compared to allogenic transfusion, was also significantly higher in cardiac surgery. However, there was still net benefit for CS in trauma surgery, with median salvaged transfusion volume of one unit, in both general & orthopedic trauma. Therefore, in centers where the cost of setting up CS, both in terms of equipment and personnel, is less than the cost of one unit of blood from blood bank, use of CS in trauma operations should be considered.
在心胸外科手术中，使用 Cellsaver（CS）设备进行自体血液再灌注是常规操作，但关于其在创伤中的应用，循证医学文献却很少。本研究比较了 2017 年至 2022 年在一家 1 级创伤中心的这两种不同人群中 CS 的使用情况。CS 在心脏和创伤病例中的成功率分别为 97%和 74%。与异体输血相比，CS 提供的血液需求比例在心脏手术中也显著更高。然而，在创伤手术中 CS 仍具有净效益，普通和骨科创伤的中位 salvaged 输血量均为 1 单位。因此，在 CS 的设置成本（包括设备和人员）低于血库 1 单位血液成本的中心，应考虑在创伤手术中使用 CS。
